RDHL · RedHill Biopharma Ltd.
$0.60
+0.00 (+0.82%)
At close · Aug 14
Market Cap
$3.65M
Shares
6.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.60
Open$0.59
Day$0.58–0.60
52W close$0.58–2.52
Avg vol 30d56K
Short int30K · 0.5% float · 1.0d
Short vol20%
Last earningsMar 31, 2022
DataAug 2024–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Aug 20, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
−20%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−38%
trailing
YTD return
−42%
this year
Relative strength
−51%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +3 funds added
Insider flow
Distributing
Net -$1.4K over 90 days · 100% sells
Short interest
Rising
0.49% of float · ▲ +49.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 3-yr range
Squeeze score
40
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
9.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +3 funds added
Insider flow
Distributing
Net -$1.4K over 90 days · 100% sells
Short interest
Rising
0.49% of float · ▲ +49.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $3
vs 200-day avg -39%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RDHL
this stock
RedHill Biopharma Ltd.
|
$3.65M | -41.8% | — | — | 0.5% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
Raw-price comparisons begin at the captured split on Aug 20, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RDHL | -0.8% | -14.9% | -37.5% | -7.7% | -41.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.2% | -19.4% | -51.3% | -11.6% | -55.6% |
Key facts
CIK
1553846
CUSIP
757468301
13F (30d)
13 filings
13 filers
Visit website
Investor relations